Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): University Hospital Halle, Martin-Luther-University Halle-Wittenberg Background and purpose The dysfunctionality of endothelial cells (EC) and smooth muscle cells (SMC) contributes to the progression of vascular remodeling and subsequent cardiovascular pathologies. Several microRNAs (miRNA) have been revealed as key regulators of EC and SMC function, therefore suggesting them as potential targets in the modulation of vascular remodeling. Here, we investigate the potential role of miR-32-5p in vascular cell function and its potential as a therapeutic target in vascular remodeling. Material and Methods Initial screenings by qRT-PCR analysis for miR-32-5p expression were performed in murine femoral artery tissue on day 10 and 21 after wire-induced injury in C57Bl6 mice, serving as restenosis model. MiR-32-5p expression was assessed using qRT-PCR in human vascular endothelial (HVECs) and human vascular smooth muscle cells (HVSMC). The role of miR-32-5p on cellular functions, as migration and proliferation, was determined by performing scratch wound and BrdU assays. Potential miR-32-5p downstream targets were identified from literature and their expression levels upon interference with miR-32-5p evaluated on mRNA and protein levels. Results MiR-32-5p expression was decreased over time in the wire-induced injury model. In vitro, miR-32-5p expression was significantly decreased in replicative senescent HVSMC and HVEC (p<0,05) and relatively higher in HVSMC than in HVEC for all conditions. Under growth conditions an elevated expression of miR-32-5p in HVEC and significantly increased expression in HVSMC was detected (p<0,01). Proliferation in HVSMC increased significantly (p<0,05) by pre-miR-32-5p transfection, but remained unaffected in HVEC. Migration of HVECs and HVSMCs was improved by miR-32-5p and decelerated after antagomiR interference. Systemic literature target research revealed several potential targets in both cell types, of which the following were significantly downregulated in HVSMC after pre-miR transfection including PIK3r3 (p<0,05), KLF4 (p<0,05), CD69 (p<0,01), MAP2K4 (p<0,05) and BCL211 (p<0,01). Additionally, CD69 and KLF4 expression increased significantly either in HVECs (p<0,05). Conclusion Our results suggest that miR-32-5p may be a substantial regulator in HVEC and HVSMC senescence and function and subsequently in vascular remodeling. To fully evaluate its role in the pathogenesis of atherosclerosis and therefore, its therapeutic potential in cardiovascular diseases, further investigations are needed. Additional experiments with the purpose of investigating miR-32-5p-target interactions and apoptotic effects will be performed shortly.

Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis

Human IL-32θA94V mutant attenuates monocyte-endothelial adhesion by suppressing the expression of ICAM-1 and VCAM-1 via binding to cell surface receptor integrin αVβ3 and αVβ6 in TNF-α-stimulated HUVECs

IL-33 Suppresses the Progression of Atherosclerosis Via the ERK1/2-IRF1-VCAM-1 Pathway.

IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids

Abstract 029: Interleukin-35 Suppresses Endothelial Activation by Inhibiting Mitochondrial Reactive Oxygen Species Mediated Site-specific Acetylation of Histone 3 Lysine 14

MiR-32-5p/AIDA Mediates OxLDL-Induced Endothelial Injury and Inflammation

MiR-32-5p as potential key mediator of vascular remodeling enhances cell proliferation of vascular smooth muscle cells

IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (histone 3 Lysine 14).

Transgenic Overexpression of IL-37 Protects Against Atherosclerosis and Strengthens Plaque Stability.

Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing Mapk-Ap-1 Pathway

Interleukin-38 in atherosclerosis

Interleukin-12p35 Deficiency Reverses the Th1/Th2 Imbalance, Aggravates the Th17/Treg Imbalance, and Ameliorates Atherosclerosis in ApoE-/- Mice

MicroRNA-29a-3p Reduces TNFα-Induced Endothelial Dysfunction by Targeting Tumor Necrosis Factor Receptor 1

IL-33 Reduces Saturated Fatty Acid Accumulation in Mouse Atherosclerotic Foci

Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice Through Regulatory T Cell Augmentation and Dendritic Cell Tolerance.

Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration

Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis

Regulation of Microrna-155 in Atherosclerotic Inflammatory Responses by Targeting Map3k10

Interleukin 6 Destabilizes Atherosclerotic Plaques by Downregulating Prolyl-4-hydroxylase Α1 Via a Mitogen-Activated Protein Kinase and C-Jun Pathway.

Expression of Interleukin (IL)-18 and Functional IL-18 Receptor on Human Vascular Endothelial Cells, Smooth Muscle Cells, and Macrophages

Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice